{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:52:28Z","timestamp":1793371948928,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["K23HL159313"],"award-info":[{"award-number":["K23HL159313"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.rpth.2025.102980","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:13:40Z","timestamp":1753226020000},"page":"102980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102980_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.ackd.2019.04.001","article-title":"Erythropoiesis-Stimulating agents and cancer: myth or truth","volume":"26","author":"Choi","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.rpth.2025.102980_bib2","first-page":"3607","article-title":"A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy","volume":"87","author":"Tepler","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102980_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0037-1963(00)90050-7","article-title":"Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia","volume":"37","author":"Vadhan-Raj","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1016\/j.rpth.2025.102980_bib4","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102980_bib5","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102980_bib6","first-page":"714","article-title":"[Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)]","volume":"40","year":"2018","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.rpth.2025.102980_bib7","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.102980_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102980_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2023.2201428","article-title":"Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia","volume":"16","author":"Song","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2025.102980_bib10","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"3","author":"Al-Samkari","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102980_bib11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2025.102980_bib12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.6004\/jnccn.2015.0166","article-title":"Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices","volume":"13","author":"Denduluri","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2025.102980_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12885-015-1038-y","article-title":"Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans","volume":"15","author":"Aspinall","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.rpth.2025.102980_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.rpth.2025.102980_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.rpth.2025.102980_bib16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-014-2416-x","article-title":"The impact of dose\/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer","volume":"73","author":"Nakayama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.rpth.2025.102980_bib17","doi-asserted-by":"crossref","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.rpth.2025.102980_bib18","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/jth.14295","article-title":"Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease","volume":"16","author":"Michelson","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102980_bib19","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood-2011-11-393900","article-title":"In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation","volume":"119","author":"Psaila","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102980_bib20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00277-018-3556-6","article-title":"Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim","volume":"98","author":"Al-Samkari","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2025.102980_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia","volume":"10","author":"Al-Samkari","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2025.102980_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/JBM.S191790","article-title":"Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease","volume":"10","author":"Cheloff","year":"2019","journal-title":"J Blood Med"},{"key":"10.1016\/j.rpth.2025.102980_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/hematology.2022000374","article-title":"Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem","volume":"2022","author":"Al-Samkari","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2025.102980_bib24","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2025.102980_bib25","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.102980_bib26","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2017.180166","article-title":"The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"103","author":"Al-Samkari","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.102980_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: a review of the literature","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.rpth.2025.102980_bib28","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.102980_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102980_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/135354","article-title":"Thrombopoietin receptor levels in tumor cell lines and primary tumors","volume":"2010","author":"Erickson-Miller","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.rpth.2025.102980_bib31","article-title":"The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy","volume":"4","author":"Liao","year":"2023","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.rpth.2025.102980_bib32","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41416-024-02630-w","article-title":"Risk and adverse clinical outcomes of thrombocytopenia among patients with solid tumors-a Danish population-based cohort study","volume":"130","author":"Adelborg","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rpth.2025.102980_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2025.102980_bib34","series-title":"NCCN guidelines version 1.2024: hematopoietic growth factors","year":"2024"},{"key":"10.1016\/j.rpth.2025.102980_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102980_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925003048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925003048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:15:15Z","timestamp":1773843315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925003048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2475037925003048"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102980","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102980"}}